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ImmunohiKtochomical application of antibodies 
against heparan  wulfate proteoglycan core protein and 
heparitinase-digcHted heparan sulfate stubs showed the 
presence of heparan  sulfate proteoglycan in all base­
ment membrano« of the ra t kidney. However, a mono­
clonal antibody (JM-403) against native heparan sulfate 
(van den Born, J», van den Heuvel, L. P. W, J., Bakker, 
M. A. II., Veerkam p, J, II., Assmann, K* J. M., and Berden, 
J, H. ML (1902) K idney In i. 41, 115-121-» largely failed to 
stain tubu lar basem ent membranes, suggesting the 
presence of heparan  sulfate chains lacking the specific 
JM-403 epitope. H eparan sulfate preparations from var­
ious sources differed markedly with regard to JM-403 
binding, as dem onstrated  by liquid phase inhibition in 
eiv/ynuviinked im m unosorbent assay, the interaction 
decreasing with increasing sulfate contents of the po­
lysaccharide. M apping of the JM-403 epitope indicated 
that it was dom inated by one or more N-unsubstituted 
glucosamine uuit(s), since treatm ents that destroyed or 
altered the n truetu re  of such units in heparan sulfate 
preparations (cleavage a t A^unsubstituted glucosamine 
units with IINO.J a t pH 3.9 and Ar-acetylafcion with acetic 
anhydride, respectively), abolished antibody binding. 
Conversely, im num oreactivity could be induced in a (n- 
glucuronyM ,'1^aeetyl-o-glucosam inyM ,4) polysaccha­
ride by the generation of iV-unsubstituted glucosamine 
units by chem ical A^deacetylation. The presence of 
N-unsubHtituted glucosamine in a JM-403-binding hepa­
ran sulfate (preparation  HS-II from human aorta) was 
dem onstrated by an 3-fold reduction in molecular size 
following HNOa (pH 3.0) treatment. Further character­
ization of the epitope recognized by JM-403, based on 
enzyme-linked im m unosorbent assay inhibition tests 
with chemically/enzymatically modified polysacchar­
ides, indicated th a t one or more Af-sulfated glucosamine 
units are invariable present, whereas 1,-iduronic acid 
and O-sulfale residues appear to inhibit JM-403 reactiv­
ity. It is concluded tha t the epitope contains one or more 
Af-unsubHtituted glucosamine and n-glucuronic acid 
units and is located in a region of the heparan sulfate
chain composed of mixed iV-sulfated and JV-acetylated 
disaccharide units.
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Proteoglycans consist of one or more glycosaminoglycan side 
chains covalently hound to a core protein (1, 2). The heparan 
sulfate proteoglycans (I-ISPGs)1 constitute a major class of pro­
teoglycans that are found in the extracellular matrix, espe­
cially in basement membranes, and at the cell surface, associ­
ated with the cell membrane (3-5). Many biological activities of 
I-ISPGs are due to interactions between the heparan sulfate 
(IIS) polysaccharide side chains and a variety of proteins, 
which include extracellular matrix molecules, enzymes, en­
zyme inhibitors, growth factors and other cytokines (2, 5-7). 
These interactions can be specific, dependent on defined sulfa­
tion patterns within given sequences of sugar residues, as 
described for antithrombin (8), basic fibroblast growth factor (9, 
10), and hepatocyte growth factor (11); others appear to be 
mainly based on relatively nonspecific electrostatic interac­
tions, and involve proteins such as lipoprotein lipase (12), 
platelet factor 4 (13) and mast cell protease I (14) (for a general 
discussion, see Ref. 15).
The biosynthesis of PIS involves the formation of a nonsul- 
fated (GlcA/Bl^-GlcNAcal^^ precursor polysaccharide, which 
subsequently undergoes a series of polymer-modification reac­
tions, These reactions start withiV-deacetylation/iV-sulfation of 
GlcNAc residues, which is followed by C-5 epimerization of 
GlcA to iduronic acid (IdoA) units, and finally by O-sulfation at 
various positions (5). The GlcA C-5 epimerization and O-sulfa- 
tion reactions occur in the close vicinity of iV-sulfate groups, 
pointing to a key role for the glucosaminyl N-deacetylase/ 
N-sulfotransferase enzyme in determining the overall extent of 
modification of the I-IS chain. Structural analysis of HS prep­
arations have revealed that the modifications tend to colocalize 
in block sequences, separated by relatively unmodified do­
mains (16-19), The extent of biosynthetic modification, affect­
ing the number, length, and substitution patterns of the mod­
ified domains as well as their position along the I-IS chain, may 
differ among cell types (20), alter during proliferation (21), and 
change as a result of cell transformation (22, 23). Structural 
analysis of HS is complicated by the fact that even highly 
purified and uniform preparations consist of mixtures of po­
ly saccharide chains that have reached different levels of mod­
ification, Monoclonal antibodies (mAbs) that specifically recog­
nize well defined epitopes in HS could be major tools in such 
analysis. We recently described the production of such an an­
1 The abbreviations used are: HSPG, heparan sulfate proteoglycan; 
HS, heparan aulfate; mAb, monoclonal antibody; ELISA, enzyme-linked 
immunosorbent assay; FITC, fluorescein isothiocyanate; PAPS, adeno­
sine 3J-phosphate 5'-phosphosulfate.
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ti-HS mAb, JM-403 (24), which has now been partially charac­
terized with regard to the epitope requirement. In the present 
report, evidence is provided that the epitope is dominated by 
the presence of an unsubstituted glucosamine residue(s). More­
over, immunohistochemical application of the mAb demon­
strates that the iV-un substituted GlcN units occur in situ , 
hence in native HS, and is not introduced as an artifact during 
the isolation procedure. The possible biological significance of 
these findings is discussed.
MATERIALS AND METHODS
Glycosaminoglycans—HS (preparation HS-II), isolated from human 
aorta essentially according to Ivei'ius (25), was provided by W. Murphy 
(University of Monash, Melbourne, Australia). Five HS preparations, 
isolated from bovine aorta, lung, intestine, and kidney (two different 
preparations), were provided by K, Yoshida (Seikagaku Corp., Tokyo, 
Japan), HS from bovine kidney (used to coat the ELISA plates) was 
purchased from Seikagaku. HS from bovine liver was as described 
previously (26). HS from pig intestine, the Escherichia coli K5 capsular 
polysaccharide, with the same (GlcA-GlcNAc)„ structure as the nonsul- 
fated HS/heparin precursor polysaccharide (27), chemically O-sulfated 
K5 polysaccharide, and iV-desulfated heparin were given by Dr. G. van 
Dedem (Organon Corp., Oss, The Netherlands). Intact heparin (stage 
14) from pig intestinal mucosa was obtained from Inolex Pharmaceuti­
cal Division (Park Forest South, IL) and purified by repeated precipi­
tation with cetylpyridinium chloride from 1.2 M NaCl (28),
Chemical / Enzymatic Modifications o f Polysaccharides—Glycosami­
noglycans were cleaved by deamination with HNOa under two sets of 
conditions. Reaction at pH 1.5 (10 min) was performed as described 
previously (29) and results in selective attack of N-sulfated GlcN units, 
with cleavage of the corresponding glucosaminidic linkages (30). Alter­
natively, deamination at pH 3.9 (29) cleaves the polysaccharide chain at 
N-unsubstituted GlcN residues (30). Following reduction with NaBH(lJ 
the deamination products (essentially ^tetrasaccharides) were recov­
ered by chromatography on Sephadex G-15. For iV-deacetylation by 
hydrazinolysis (31), samples (1 mg) of polysaccharides were dissolved in 
1 ml of hydrazine hydrate (Fluka; H20  content, 36%) containing 1% 
(w/v) hydrazine sulfate and heated in sealed glass tubes at 96 °C, After
4 h, the samples were repeatedly evaporated to dryness and desalted on 
PD-10 columns (Pharmacia Biotech Inc.) according to the instructions 
of the manufacturer. ZV-Acetylation by treatm ent with acetic anhydride 
was performed as described by Danishefsky and Steiner (32), Com­
pletely (N - and 0-) desulfated, TV-deacetylated heparin was prepared 
according to Jacobsson et aL (33).
For heparin lyase digestion, samples (1 mg) of HS were dissolved in 
200 /zl of 50 mM tlEPES, pH 7,0, 1 mM CaCl2, containing 10 milliunits 
of heparitinase (Seikagaku, enzyme also known as heparinase III, EC 
4.2.2.8) or 10 units of heparinase I (Sigma; EC 4.2.2.7) and incubated at 
37 °C for 5 h. To ensure end-point digestion, the same amount of 
enzyme was added again twice for additional 5- and 10-h incubation 
periods (total incubation time, 20 h). Reactions were terminated by 
inactivation of the enzymes by heating at 96 °C for 5 min. The super- 
natants obtained after centrifugation at '13,000 rpm for 5 min were 
recovered.
Native and modified polysaccharides were analyzed by gel chroma­
tography on a column (1 X 90 cm) of Sephacryl S-300 in 0.5 m NaCl, 
eluted at a rate of 4.8 ml/h. Effluent fractions of 1.6 ml were collected 
and analyzed for hexuronic acid by the carbazole reaction (34).
Immunochemical Procedures—Indirect immunofluorescence was 
performed as described previously (35) on 2-jLtm rat kidney cryostat 
sections. The antibodies used were a goat antibody toward human 
glomerular basement membrane HSPG core protein, coded B131 (36); 
four different mouse an ti-HS mAbs (all IgM) designated JM-403 (24), 
JM-13 (37), HepSS-1 (38) (Seikagaku), and 10E4 (39) (gift from Dr. G. 
David, Leuven, Belgium); and the mouse mAb 3G10 (IgG2b), reacting 
with HS stubs generated by heparitinase digestion (39) (gift from Dr. G. 
David). As secondary antibodies we used FITC-labeled rabbit anti-goat 
IgG (Dako, Glostrup, Denmark), FITC-labeled goat anti-mouse IgM(Fc) 
(Nordic, Tilburg, The Netherlands), and FITC-labeled F(ab' ^ -frag­
ments of sheep anti-mouse IgG (Organon Teknika, Turnhout, Belgium). 
Control experiments in which the FITC-labeled secondary antibodies 
were applied to the sections without prior pi’imary antibody incubation 
were consistently negative. In double-staining experiments, sections 
were blocked using an avidin/biotin blocking kit (Vector, Burlingame, 
CA) and were then incubated with anti-HS mAb JM-13 followed by 
tetramethylrhodamine isothiocyanate-labeled goat anti-mouse IgM (Fc)
(Nordic). Thereafter, biotinylated anti-HS mAb JM-403 was applied to 
the sections and visualized using FITC-labeled cxtravidine (Southern 
Biotechnology Associates Inc., Alabama, AL). The double staining ex­
periments included the following controls: (a) omitting biotinylated 
mAb JM-403 or mAb JM-13 or both; (b) incubating with mAb JM-13 
followed by extravidine-FITC. N-Acetylation of primary amino groups 
within the sections was done by applying 0.5 M borate buffer (pH 9.0) 
containing 2.5 ¡xl of acetic anhydride/ml for 3 X 10 min onto the 
sections. These were then washed in phosphate-buffered saline, and the 
routine immunofluorescence procedure was initiated. The effect of N- 
acetylation was ascertained by applying iluoroHcamine (Sigma), a flu- 
orogenic reagent for primary aminos, onto the sectioivs. Sections wore 
examined on a Zeiss Axioskop microscope equip pod for fluorescence
microscopy.
The JM-403 inhibition ELISA on IiS-coated platen was per formed as 
described previously (40) and is based on the inhibition of mAb JM-403 
binding to coated HS by liquid phase polysaccharides. Percentage inhi­
bition was calculated as (1 -  (A<mo with inhibitor/Aliri„ withoul inhibi­
tor)) X 100%. ICr>() (ng of HS/ml) is defined as the concentration of IiS 
that gives 50% inhibition in the ELISA ays Lem.
Statistics—The correlation boLween degree of IIS sulfation and ICR0 
in the JM-403 inhibition ELISA was calculated using the Spearman 
rank correlation test; p < 0.05 was regarded as significant.
RESULTS
Expression o f the JM -403 Epitope in D ifferent H eparan S u l­
fates—Immunofluorescence with anti-H S mAl) JM -403 on cry­
ostat sections showed the presence of the cognate epitope in a 
variety of basem ent membranes, us demon s t  ra ted  in Fig. 1A for 
the ra t  kidney. The glomerular basem ent m em brane Btainod 
most intensely, along with Bowman*« capsule and the basal 
lam ina surrounding vascular smooth muscle cells. By contrast, 
the tubular basem ent m em branes weixj largely negative, On 
the other hand, all renal basem ent m em branes were s ta ined  by 
an antibody against the core protein of a H SPG  derived from 
hum an  glomerular basem ent m em brane (Pig. IB). They were 
likewise positive for mAb 3G10, which reacts  with the residual 
PIS stubs rem aining after enzymatic cleavage by hepuritinuse 
(Fig. 1C), The resu ltan t 3G10 epitope contains an essential, 
term inal, 4 ,5-unsaturated  uronate residue and  thus  can serve 
as a  general I~IS m arker (39), These resu lts  indicate the pres­
ence of HSPG molecules in all renal basem ent m em branes, 
only some of which contain the JM -403 epitope. To streng then  
this conclusion, we performed double-staining experim ents on 
ra t  kidney cryostat sections, using biotinylated mAl) JM-403 
and another anti-HS mAb (JM-13), which also shows a selec­
tive basem ent m em brane stain ing  (37). We th u s  found HS 
positive tubular basem ent m em branes w ith an ti-H S mAb 
JM-13 (Fig. 2A), which are negative (or below the detection 
lim it of the method) for JM-403 (Fig. 2B).
The heterogeneity ofHS preparations with regard  to JM-403 
binding was furtherm ore dem onstrated by testing  the inhibi­
tory c ap acity of ei gh t  IIS preparations, isolated Fro m d i fib re n t 
sources, in the JM-403 ELISA. The resu lts  (Table I) clearly 
dem onstrate a great variability in antibody binding to these HS 
preparations. Interestingly, the sulfate content of these po­
lysaccharides correlated w ith the IC n0 (p  ^  0.0011) in the 
JM-403 ELISA, indicating tha t the JM -403 epitope is predom ­
inan tly  found in low sulfated ( < 1.0 sulfate group/disaccharide 
unit) HS species.
The JM -403 Epitope Is Dependent on the Presence o f an  
N-Unsubstituted. Glucosamine Residue(s)— In order to further 
define the  JM-403 epitope, HS from h u m an  ao rta  (HS-II) was 
selectively degraded so as to allow the sep ara te  isolation of 
TV-sulfated and iV~acetylated block s truc tu res . A^-Sulfated oli­
gosaccharides were isolated after deacetylation of GlcN Ac res­
idues using hydrazinolysis followed by exhaustive dea mi nation 
a t  pH 3.9, which results in cleavage of the polysaccharide a t  the 
iV -unsubstitu ted  u n its  (see “M ate r ia ls  and  M ethods”). N~ 
Acetylated oligosaccharides were recovered following exhaus-
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F ig. 2. D ouble-sta in ing  of h e p a ra n  su lfa te  in  r a t  k idney  cryo­
s ta t  sections by in d ire c t  im m unofluorescence. A, anti-HS mAb 
JM-13; B , anti-HS mAb JM-403. Arrows indicate tubular basement 
membranes positive for JM-13 but negative for JM-403. Magnification, 
x 350.
Fig. 1. In d irec t im m unofluorescence stain ing of r a t  k idney 
cryosta t sections. A, anti-HS mAb JM-403; B> anti-HSPG-core protein 
antibodies; C, anti-HS-stub mAb 3G10. Magnification, x 350. For fur­
ther experimental data seo “Materials and Methods.”
tive deamination of the polysaccharide at pH 1,5, which cleaves 
the polysaccharide at iV-sul fated GlcN residues. The results 
shown in Fig. 3A demonstrate loss of JM-403 binding for the 
A/-sulfated as well as the iV-acetylated oligosaccharides derived 
from HS-II. Unexpectedly, pH 3.9 deamination alone, z.c. not 
proceeded by AT-deacetylation, also abolished antibody reactiv­
ity, pointing to the presence of N-unsubstituted GlcN in HS-II 
and to a role for an N-unsubstituted GlcN residue(s) in anti­
body recognition. Conversely, generation of iV-un substituted 
GlcN by iV-deacetylation not followed by deamination resulted 
in increased JM-403 binding. Further evidence for an essential 
role of TV-unsubstituted GlcN derived from the complete loss of 
reactivity following chemical N ~acetylation of HS-II using ace­
tic anhydride (Fig. 3A). In addition, however, N -sulfated GlcN 
residues would seem to be important, as indicated by the loss of 
antibody binding after deamination at pH 1.5.
Presence o f N-Unsubstituted Glucosamine Units in Native 
H S—The presence of JV-un substituted GlcN units in native 
HS-II was investigated by gel chromatography on Sephacryl
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Table I
Inhibitory capacity o f HS  preparations in the JM-403 ELISA, 
illustrating the relationship between sulfation and HS binding
-  m . t  ^  A  .  J V % 1  V * 1  Y
0.20
r = 0.95; p  = 0.0011)
HS preparation Sulfate groups/di saccharide l e «
ng HS ! ml
Human aorta0 0.60 300
Bovine aorta6 0.56 320
Bovine kidney (l.l)6 0.84 392
Bovine lung4 0.91 331
Bovine intestine6 0.98 1113
Bovine kidney (1.25)* 1.01 1872
Bovine liver r 1.50 >5000
Pig intestine^ 1.64 >5000
a See Ref. 25.
h M. Maccarana, Y. Sakura, A. Tawada, K. Yoshida, and U. Lindahl, 
submitted for publication. The two preparations of kidney IiS  differed 
by the concentrations of the NaCl solutions (1.1 and 1.25 m) required to 
elute the polysacchai'ides from Dowex 1-X2. 
c See Ref. 26.
d As determined by Organon.
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Fig. 3. Fluid phase inhibition of JM-403 binding to kidney hepa­
ran sulfate by chemically modified HS-II, K5, and heparin prepa­
rations. Dose-response inhibition curves were generated as described 
under “Materials and Methods.” A, native HS-II (•); iV-deacetylated HS-II 
(+); HS-II treated with HN02 at pH 1.5, HS-II treated with HN02 at pH 
3.9, N-deacetylated HS-II treated with HNOa at pH 3.9, or iV-acetylated 
HS-II (O; all samples showing lack of reactivity). B , iV-deacetylated K5 
polysacchatide (•); A^O-desulfated, N-deacetylated heparin (+); 
N-deacetylated, O-sulfated K5 polysaccharide (■); native K5 polysaccha­
ride, native heparin, ZV-deacetylated heparin, iV-desulfated heparin (O).
S-300, before and after exhaustive deamination of the polysac­
charide at pH 3.9. A shift of the peak elution position, corre­
sponding to a decrease in M r from ~ 4 5  X 103 to 12-15 X 103,
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F ig . 4. Effect of high-pH deamination on HS-II. Samples of HS-II 
were subjected to gel chromatography on Sephacryl S-300, as described 
under “Materials and Methods,” before (O) and after ( • )  treatment with 
HNOa at pH 3.9. Effluent fractions were analyzed for hexuronic acid by 
the carbazole reaction, The elution pattern of a sample oF HS-II lhaL 
had been subjected to chemical N-acetylation followed by deamination 
at pH 3.9 was essentially unchanged compared with that of native, 
untreated HS-II (data not shown).
was observed (Fig. 4), suggesting the presence of, on the aver­
age, two or three N-unsubstituted GlcN units/chain. By con­
trast, HS-II that had been previously iV-acetylated by reaction 
with acetic anhydride resisted deamination under these condi­
tions. This control experiment ascertained that deaminative 
cleavage at pH 3.9 is indeed restricted to JV-unsubstituted GlcN 
residues.
N-Acétylation of kidney cryostat sections with acetic anhy­
dride abolished all staining due to mAh JM-403 (data not 
shown). This treatment simultaneously precluded staining of 
the section with fluorescamine, as expected for acétylation of 
primary amino groups. By contrast, the staining intensities of 
three other anti-HS mAbs (JM-13, 10E4-, and HepSSl) as well 
as of the anti-HSPG core antibody B131, were only marginally 
affected by the treatment with acetic anhydride (data not 
shown). These findings indicate that unsubstituted amino 
groups do indeed occur in native HS, as present in tissue 
sections that have not been treated or fixed in any way (see Fig. 
1A) and confirm our conclusion that iV-unsubstituted GlcN 
units are essential for recognition by mAh JM-403.
Recognition of Chemically Modified Heparin and E. coli K5 
Capsular Polysaccharides by mAb JM-403—Neither the non- 
sulfated E. coli K5 capsular polysaccharide, which has the 
same (GlcA-GlcNac),, structure as the unmodified biosynthetic 
precursor of hepai'in/HS (27), nor native heparin, which is 
extensively modified and carries ^2,5 sulfate groups/disaccha­
ride unit, showed any binding to JM-403 (Fig. SB), JV-Deacety- 
lating the polysaccharides by hydrazinolysis induced strong 
antibody reactivity in the K5 polysaccharide, but not in heparin 
(Fig. SB). These findings demonstrate that a structure com­
posed of alternating GlcA and N-unsubstituted GlcN units, 
joined by the appropriate linkages, is sufficient for antibody 
recognition. Why is the iV-deacetylated heparin, which is ex­
pected to contain 2-3 AT-unsubstituted GlcN units/chain (41), 
not recognized by JM-403? Since N- de sulfation of heparin also 
failed to induce JM-403 reactivity (Fig. SB), it seemed likely 
that factors other than the availability of ¿V-unsubstituted 
GlcN units would have to be considered.
iY-Deacetylated, iV/O-desulfated (“naked”) heparin differs 
from N-deacetylated K5 polysaccharide in one major regard, 
Le. the occurrence of IdoA units. The effects of these constitu­
ents were evaluated by testing AT-deacetylated K5 polysaccha­
ride as well as naked heparin in the JM-403 inhibition ELISA.
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T ablis I I
JM-403 reactivity o f selectively degraded HS-II
Treatment Effect on heparan sulfate1 JM-403 reactivity 
IC50 (ng HS/ml)
None 300
Heparinase I
Heparitinase
HNOz pH: 1.5
□ □ (500
> 5000
> 5000
n The scheme illustrates the predicted effects of the various treat­
ments on different regions of the HS chain. The symbols define 
N-acetylated, unmodified regions (—); JV-sulfated, heavily modified 
(O-sulfate and IdoA-rich) regions (■); and mixed N-acetylated and 
JV-sulfated regions (□).
The inhibitory activity of naked heparin was '-'100-fold lower 
than that of the JV-deacetylated K5 polysaccharide (Fig. 3B). 
Since the naked heparin differs from the iV-deacetylated K5 
polysaccharide merely by the presence of IdoA, it is inferred 
that such units interfere with antibody binding; the residual 
activity is probably associated with the limited number of GleA 
residues present in the polymer (—20% of the total hexuronic 
acid contents (41)). Contrary to the native heparin, JV-deacety- 
lated heparin and iV-desulfated heparin, the naked heparin 
was reactive (Fig. 3B), indicating that removal of O-sulfate 
groups exposed epitope structures. To confirm the negative 
effect of O-sulfate groups on JM-403 binding, we compared in 
the ELISA the inhibition induced by N -deacetyl a ted K5 po­
lysaccharide with that of the JV-deacetylated, O-sulfated ana­
log. This latter K5 derivative contains an average of 1.2 
O-sulfate (but no JV-sulfate) groups/disaccharide unit. The lo­
cations of the O-sulfate groups were not defined but would 
presumably primarily involve G-6 of the GlcN units, along with 
C-2 and/or C-3 of the GlcA units. The results in Fig. SB clearly 
show that O-sulfation of ¿V-deacetylated K5 polysaccharide 
strongly reduces JM-403 binding.
Taken together, these data explain the lack of JM-403 reac­
tivity toward native, N-deacetylated, or N-desulfatcd heparin, 
and, moreover, conform to the observed decrease in antibody 
binding to HS prepai’ations with increasing degree of sulfation 
(hence, increasing IdoA contents (42)). Furthermore, the exper­
iments demonstrate that neither (N- or 0-) sulfate groups nor 
N-acetyl groups are required for JM-403 binding, since 
N-deacetylated K5 (and naked heparin) lack such groups yet 
are recognized by the antibody,
Location o f JM-403 Epitopes in the HS Chain—In order to 
define the location of the JM-403 epitope along the HS chain, 
samples of HS-II were enzymatically or chemically degraded 
using reagents/conditions with well defined cleavage specific­
ity. The resultant oligosaccharides were then tested in the 
JM-403 ELISA (Table II). As indicated above, cleavage of HS-II 
at N-sulfated GlcN residues by the HNO^/pH 1.5 procedure 
abolished all binding to JM-403 (Fig. 3A). This finding excludes 
an epitope consisting of merely iV-unsubstituted and JV-acety- 
lated disaccharide units. On the other hand, JV-sulfate groups 
are not required for JM-403 binding (as shown by the 
N-de acetyl ated K5 sample; Fig. SB). These results there fore 
indicate that JV-sulfate groups, while not essential for reactiv­
ity, are tolei'ated, and, in addition, are invariably present in the 
IiS epitope. In fact, complete loss of reactivity occurred on low 
pH deamination of six different IiS preparations from different 
sources (the inhibitory samples from Table I), Digestion of 
HS-II by heparitinase (heparinase III) also abolished all reac­
tivity. This enzyme cleaves glucosatninidic linkages between
either iV-acetylated or iV-sulfated GlcN residues and nonsul- 
fated hexuronic acid units. By contrast, HS-II binding to 
JM-403 was found to be essentially insensitive to heparinase I, 
which cleaves glucosaminidic linkages between AT-sulfated 
GlcN and 2-O-sulfated IdoA units. The epitope is thus in all 
probability located outside the heavily modified, heparin-like, 
JV-sulfated block sequences of the HS chain. The most likely 
site for such a structure is in regions composed of mixed 
N-acetylated and iV-sulfated disaccharide units, with a relative 
high GlcA content, at the boundaries between unmodified and 
highly sulfated blocks of IiS (Table II).
DISCUSSION
The present study deals with the saccharide recognition 
properties of anti-HS mAb JM-403, the generation and basic 
characteristics of which were described previously (24). Apply­
ing the antibody to immunofluorescence studies on rat kidney 
sections l'evealed that the carbohydrate epitope is not evenly 
distributed among the HS subspecies of this tissue. All base­
ment membranes, as expected, were found to contain IiSPGs, 
as evidenced using other antibodies. However, the polysaccha­
ride present in tubular basement membranes stained poorly 
with JM-403, suggesting the existence of HS-isoforma lacking 
the corresponding epitope. It thus seemed important to char­
acterize this epitope with regard to saccharide structure.
The results of such studies demonstrated a critical role for an 
N-unsubstituted GlcN unit(s) within the epitope. The occur­
rence of these residues in appropriate linkage to GlcA units 
suffices to induce strong antibody binding, However, the natu­
rally occurring epitope(s) in native HS chains apparently have 
a more complex structure. The results of chemical and onzy- 
matic degradation experiments suggest that the HS epitopes 
contain not only GlcA units but also JV-sulfated GlcN residues, 
whereas IdoA units and O-sulfate groups appear to impede 
antibody recognition. Such struclures are likely to be found in 
regions of the HS chains that contain mixed N-acetyluted and 
N-sulfated sequences. It seems probable that N-unsubstitutod 
GlcN units in a highly JV- and O-sulfated, IdoA-rich surround­
ing, as presumably occurring also in heparin (43), will escape 
detection by JM-403. Indeed, we cannot exclude that the 
epitope represents only a minor proportion of the N-unsubsti- 
tuted GlcN units in IiS and that such units occur in multiple 
structural contents.
Considering possible mechanisms for the generation of GlcN 
units with unsubstituted amino groups, there are two major 
alternatives (disregarding the theoretical but unlikely possibil­
ity of a UDP-GlcN sugar nucleotide precursor containing an 
JV-unsubstituted GlcN unit). The normal conversion of N - 
acetylated to N-sul fated GlcN units in hoparin/HS biosynthesis 
is catalyzed by a single enzyme protein, which is capable of 
promoting both the JV-deacetylation and the JV-aulfation reac­
tions. Two related yet distinct glucosaminyl N-deacefcylase/N- 
sulfotransferase enzymes have been described, one from rat 
liver (.44) and the other from mouse mastocytoma (45), that 
differ with regard to size of mENA transcript, amino-acid se­
quence, cofactor requirement, and kinetic properties (46-48), 
While the interrelationship between these enzymes with re­
gard to the biosynthesis of heparin and HS is unclear, both 
enzymes express both catalytic activities, which normally ap­
pear to be tightly coupled. However, under the appropriate 
experimental conditions the two activities are readily dissoci­
ated. Thus, formation of a heparin precursor polysaccharide by 
incubating a mouse mastocytoma microsomal fraction with 
UDP-GlcA and UDP-GlcNAc, but in the absence of adenosine 
3'-phosphate 5'-phosphosullate (PAPS), yields a product in 
which about one-third of the GlcN units are JV-deacetylated and 
have an unsubstituted amino group (49). Indeed, recent exper-
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iments showed that incubation of the intact K5 polysaccharide 
with microsomal enzymes, or with the purified iV-deacetylase/ 
2V-sulfotransferase from mouse mastocytoma, in the absence of 
PAPS, will result in the formation of iV-unsubstituted GlcN 
units that are recognized by mAb JM-403.2 A similar effect can 
be achieved by treating intact cells with chlorate, which will 
block the formation of PAPS (50). It is possible that limited 
formation of iV-unsubstituted GlcN units may occur during the 
normal biosynthesis of HS, by iV-deacetylation of selected (?) 
target GlcNAc residues that is not followed by TV-sulfation, or 
after completion of the biosynthesis, maybe in the extracellular 
space.
An alternative mechanism for the creation of N-unsubsti- 
tuted GlcN units would involve the action of an endosulfami- 
dase (JV-sulfatase). While sulfamidases have been implicated in 
HS metabolism, these enzymes seem to act in an exolytic fash­
ion, at the nonreducing terminus of the chain (51). No endoen- 
zyme of the type required to generate the JM-403 epitope has 
yet been described. Notably, however, Dawes and Pepper (52) 
proposed that heparin and HS may be extensively desulfated 
without depolymerization in vascular endothelial cells. Al­
though not yet verified, these results would imply the existence 
of a sulfatase(s) acting on the intact polysaccharide chain.
The demonstration of N~unsubstituted GlcN units in native 
HS preparations raises intriguing questions regarding the bi­
ological significance of these constituents. It has been reported 
that endothelial heparin-related molecules can bind to L-selec- 
tin (53). Eecently, this ligand, associated with the cultured cells 
or secreted into the medium/extracellular matrix, was identi­
fied as HS (54). Surprisingly, these l-selectin-binding PIS 
chains were found to be enriched in iV-unsubstituted GlcN 
residues, suggesting a role for the free amino groups in 
L-selectin binding or in the control of the biosynthetic process 
leading to the formation of L-selectin-binding saccharide se­
quences (54). The L-selectin binding HS species were produced 
by cultured bovine endothelial and human umbilical vein en­
dothelial cells but not by Chinese hamster ovary cells. These 
findings correlate to our demonstration of strong JM-403 stain­
ing of vascular basement membranes (which are produced by 
endothelial cells). Functionally, this might indicate that vascu­
lar basement membranes are capable of binding leukocytes, 
which constitutively express L-selectin on their cell surface. 
Other potential important biological activities of vascular HS, 
to be considered in this context, include anti-proliferative effect 
on arterial smooth muscle cells (16), inhibition of mesangial 
cell growth (55), and inhibition of angiogenesis (56).
We have previously shown that intravenous injection of mAb 
JM-403 into rats leads to instantaneous albuminuria (24). We 
hypothesized that this effect was due to blocking of the anionic 
charges of HS in the glomerular basement membranes by the 
antibodies. Alternatively, binding of JM-403 to epitopes con­
taining A^unsubstituted GlcN units might interfere in a more 
specific manner with the interactions between HS and other 
basement membrane constituents, thus inducing a more leaky 
ultrastructure. The possible influence of the iV-unsubstituted 
G-lcN units on the interaction between HS and other extracel­
lular matrix molecules should be investigated.
The expression of the JM-403 epitope by glomerular base­
ment membrane HS is decreased in glomerular diseases that 
are characterized by mesangial matrix expansion and/or pro­
teinuria (57). This finding could be explained by (a) masking of 
HS by cationic molecules or immune complexes; (b) decreased 
synthesis and/or increased degradation of HS; (c) an altered
2 1. Eriksson, J. van den Born, and L. Kjellén, unpublished 
observation.
structure of HS resulting in loss of the JM-403 epitope, for 
instance, due to loss of iV-unsubstituted GlcN units and/or HS 
oversulfation. The latter alternative has potential implications 
with regard to the activities of growth factors that are modu­
lated through interactions with HS (58-61) and, furthermore, 
are known to be involved in various forms of glomerulonephri­
tis (62, 63).
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